Published in AIDS Weekly, September 6th, 1999
BTG has been marketing Oxandrin (oxandrolone, USP) in the United States since 1995. Oxandrolone is indicated for the treatment of involuntary weight loss associated with chronic infection, severe trauma, burns, and unknown...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.